1933 - 1998

Odette Cancer Centre – A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

It seems we can’t find what you’re looking for. Perhaps searching can help.